{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T19:10:42Z","timestamp":1775329842129,"version":"3.50.1"},"reference-count":19,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2018,9,25]]},"abstract":"<jats:p>We report a case of a middle-aged woman who initially presented with a painful solitary destructive lesion at fifth lumbar vertebra. The initial diagnosis of plasma cell neoplasm was made based on limited histological information obtained from fragmented tissue sample. Clinicopathological findings were consistent with a solitary plasmacytoma, and she was treated with definitive radiotherapy. A month after completing radiotherapy, she was found to have multiple liver lesions. Subsequent liver biopsy confirmed plasmablastic lymphoma (PBL). She was treated with multiple lines of chemo\/immunotherapy regimens with limited or no response. She died of progression of liver lesions causing hepatic failure 16 months post diagnosis. Because of its rarity and heterogeneous presentations, PBL could easily be overlooked clinically and pathologically in immunocompetent patients. Diagnosis of PBL should be considered when there is coexpression of myeloma and lymphoma immune markers.<\/jats:p>","DOI":"10.1136\/bcr-2018-225374","type":"journal-article","created":{"date-parts":[[2018,10,21]],"date-time":"2018-10-21T13:05:13Z","timestamp":1540127113000},"page":"bcr-2018-225374","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Plasmablastic lymphoma masquerading solitary plasmacytoma in an immunocompetent patient"],"prefix":"10.1136","volume":"2018","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3358-5458","authenticated-orcid":false,"given":"Rodrigo","family":"Diaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julan","family":"Amalaseelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Imlay-Gillespie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,10,21]]},"reference":[{"key":"2025042706352927000_2018.oct19_1.bcr-2018-225374.1","unstructured":"Swerdlow SH . WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC, 2017."},{"key":"2025042706352927000_2018.oct19_1.bcr-2018-225374.2","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000234"},{"key":"2025042706352927000_2018.oct19_1.bcr-2018-225374.3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-567479"},{"key":"2025042706352927000_2018.oct19_1.bcr-2018-225374.4","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.5858\/arpa.2016-0232-RA","article-title":"Plasmablastic lymphoma: a review of clinicopathologic features and differential diagnosis","volume":"140","author":"Harmon","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"2025042706352927000_2018.oct19_1.bcr-2018-225374.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.03.008"},{"key":"2025042706352927000_2018.oct19_1.bcr-2018-225374.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.06.023"},{"key":"2025042706352927000_2018.oct19_1.bcr-2018-225374.7","unstructured":"Guidelines Version NCCN, 2014. AIDS-Related B-Cell lymphomas http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nhl.pdf (accessed 18 Sep 2014)."},{"key":"2025042706352927000_2018.oct19_1.bcr-2018-225374.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.0038"},{"key":"2025042706352927000_2018.oct19_1.bcr-2018-225374.9","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/10428194.2015.1050666","article-title":"Bortezomib plus CHOP for the treatment of HIV-associated plasmablastic lymphoma: clinical experience in three patients","volume":"57","author":"Fernandez-Alvarez","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"2025042706352927000_2018.oct19_1.bcr-2018-225374.10","first-page":"57","article-title":"Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium","volume":"2016","author":"Noy","year":"1731","journal-title":"Leuk Lymphoma"},{"key":"2025042706352927000_2018.oct19_1.bcr-2018-225374.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.0038"},{"key":"2025042706352927000_2018.oct19_1.bcr-2018-225374.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2014.03.002"},{"key":"2025042706352927000_2018.oct19_1.bcr-2018-225374.13","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/bjh.13300","article-title":"Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma","volume":"169","author":"Castillo","year":"2015","journal-title":"Br J Haematol"},{"key":"2025042706352927000_2018.oct19_1.bcr-2018-225374.14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000455146","article-title":"A case of plasmablastic lymphoma achieving complete response and durable remission after lenalidomide-based therapy","volume":"40","author":"Schmit","year":"2017","journal-title":"Oncol Res Treat"},{"key":"2025042706352927000_2018.oct19_1.bcr-2018-225374.15","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s00277-016-2732-9","article-title":"Plasmablastic lymphoma: successful management with CHOP and lenalidomide in resource constraint settings","volume":"95","author":"Yanamandra","year":"2016","journal-title":"Ann Hematol"},{"key":"2025042706352927000_2018.oct19_1.bcr-2018-225374.16","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00277-016-2904-7","article-title":"Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapy","volume":"96","author":"Pretscher","year":"2017","journal-title":"Ann Hematol"},{"key":"2025042706352927000_2018.oct19_1.bcr-2018-225374.17","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.3109\/10428194.2015.1016931","article-title":"Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphoma","volume":"56","author":"Carras","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2025042706352927000_2018.oct19_1.bcr-2018-225374.18","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3816\/CLM.2009.n.065","article-title":"Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report","volume":"9","author":"Sher","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"2025042706352927000_2018.oct19_1.bcr-2018-225374.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-225374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T13:35:37Z","timestamp":1745760937000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-225374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,21]]},"references-count":19,"alternative-id":["10.1136\/bcr-2018-225374"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-225374","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,21]]}}}